Research programme: macrophage-based nanoparticle delivery systems - Baxter Healthcare

Drug Profile

Research programme: macrophage-based nanoparticle delivery systems - Baxter Healthcare

Alternative Names: NP-IDV-BMMs - Baxter; PTX-NP-BMMs

Latest Information Update: 08 Mar 2011

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Baxter Healthcare Corporation
  • Class Paclitaxels; Pyridines
  • Mechanism of Action HIV protease inhibitors; Tubulin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Brain cancer; HIV-1 infections

Most Recent Events

  • 19 Nov 2008 Pharmacodynamics data from a preclinical trial in Brain cancer presented at the 38th Annual Meeting for the Society of Neuroscience (SfN-2008)
  • 07 Nov 2007 Preclinical trials in Brain cancer in USA (Parenteral)
  • 07 Nov 2007 Preclinical pharmacodynamics data presented at the 37th Annual Meeting of the Society for Neuroscience (SfN-2007)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top